Background Continuous compensation of dopamine represents an ideal symptomatic
treatment for Parkinson's disease (PD). The feasibility in intracerebroventricular …

In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main
pathological hallmark that requires continuous and focal restoration. Current predominant …

Continuous dopaminergic stimulation is a therapeutic strategy for the management of
Parkinson's disease, which proposes that dopaminergic agents that provide continuous …

Levodopa continues to be the most effective agent for the symptomatic treatment of
Parkinson's disease. No other drug matches its ability to suppress parkinsonian symptoms …

Control of movement depends on the continuous release of dopamine by neurons in the
basal ganglia of the brain. The degeneration of these neurons in Parkinson's disease (PD) …

Continuous dopaminergic stimulation is a therapeutic concept for the management of
Parkinson's disease (PD) that proposes that continuous, as opposed to discontinuous or …

The MPTP-treated primate has proved to be a highly predictive model of the effects of
dopaminergic drugs in the symptomatic treatment of Parkinson's disease (PD) and for the …

The contribution of non-dopaminergic degeneration to disability in Parkinson's disease (PD)
is still debated. It has been argued that no additional advance can be expected in the …

Striatal dopamine deficiency is the core feature of the pathology of Parkinson's disease (PD),
and dopamine replacement with l-3, 4-dihydroxyphenylalanine (l-DOPA) is the mainstay of …

L-dopa remains the mainstay of treatment for Parkinson disease (PD) and is the single most
effective treatment for all its cardinal features. However, although L-dopa remains effective …